This blog is written by Tom Hughes, CEO of Navitor Pharma, as part of the From The Trenches feature of LifeSciVC. We finally are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. As with most professions – especially those that involve longer-term outcomes – the way people get good at BD is

The dreaded “lockup expiry” is something all newly-minted public biotechs begin to worry about shortly after their offerings. The fear seems reasonable: venture investors and other large shareholders, now free to trade, dump large amounts of stock into the market

This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC When I first moved from the UK to the US, I told my parents that there was more biotech

The biotech IPO market continues to march forward, with five new offerings expected to price in the next week or so. Investor demand for stories advancing novel innovative therapies remains at historic levels – extending what is now over a

The biotech sector is unique relative to the rest of the stock market in many ways, but one that is often overlooked: its expansionary public equity market footprint. It’s been well appreciated by market analysts that the universe of U.S.

Biotech is booming, with eye-popping new financings seemingly announced daily. The sector is having an epic year for startup fundraising, breaking records for what will end up as the most active private biotech financing year ever. Although overall sentiment in

This blog was written by Jeb Keiper, CFO & CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Elon Musk has a flare for the dramatic, shocking Wall Street (and others) the first week

This blog was written by Tariq Kassum, COO of Obsidian Therapeutics, as part of the From The Trenches feature of LifeSciVC. Early in the morning of April 24, 2018, I woke with a knot in my stomach because I knew

Most conventional small molecule drugs engage directly with the engine of a protein’s function, aiming to often turning off an enzymatic activity associated with a disease. These drugs bind and compete against the natural substrate of the protein at what

Last week, AvroBio and Magenta Therapeutics priced their IPOs on the same night. Less than three months earlier, Unum Therapeutics priced its IPO. All three biotech companies are emerging leaders in the cell and gene therapy space, broadly defined. They

This blog was written by Jonathan Montagu, CEO and co-founder of Hotspot Therapeutics, as part of the From The Trenches feature of LifeSciVC.   In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around